$SAB Biotherapeutics (SABS.US)$ NEWS FDA Provides Clearance to IND Application for Type 1 Diabetes Therapy SAB-142 by SAB Biotherapeutics SAB Biotherapeutics (Nasdaq: SABS) announced that the FDA has cleared its IND application for SAB-142, a type 1 diabetes therapy, to proceed to a Phase 1 clinical trial in the US. SAB-142, a human anti-thymocyte immunoglobulin (hIgG), aims to delay the onset or progression of type 1 diabetes. The ongoing HUMAN trial will assess the safety, tolerability, pharmac...
SAB Biotherapeutics股票讨论区
保持警惕 👀
SAb BIO在欧洲糖尿病研究协会年会上提供了SAb-142临床试验进展更新。
SAb-142已成功招募了所有计划中的健康志愿者群体,并正准备招募研究的最后一个群体,该群体为1型糖尿病患者。
SAb-142的目标剂量为2.5mg/kg,未观察到血清病反应。
SAb-142计划在年底前完成第一阶段的头条数据公布。
美国食品药品监督管理局(FDA)批准SAb Biotherapeutics的SAb-142型1型糖尿病治疗药物的IND申请
NEWS
FDA Provides Clearance to IND Application for Type 1 Diabetes Therapy SAB-142 by SAB Biotherapeutics
SAB Biotherapeutics (Nasdaq: SABS) announced that the FDA has cleared its IND application for SAB-142, a type 1 diabetes therapy, to proceed to a Phase 1 clinical trial in the US.
SAB-142, a human anti-thymocyte immunoglobulin (hIgG), aims to delay the onset or progression of type 1 diabetes. The ongoing HUMAN trial will assess the safety, tolerability, pharmac...
$Femto Technologies (BCAN.US)$ $SAB Biotherapeutics (SABS.US)$ $Macatawa Bank (MCBC.US)$ $Dragonfly Energy (DFLI.US)$ $My Size (MYSZ.US)$ $SoundHound AI (SOUN.US)$ $比特币ETF-21Shares (ARKB.US)$
📊⚡️📊 #stock_drift24
⭐️仅供参考,不构成投资建议⭐️
资讯
SAb生物制品提供SAb-142试验更新
SAb生物制品公司(纳斯达克:SABS)提供了关于SAb-142试验的更新,报告完成对第三群体的剂量给药,并没有观察到血清病的情况。这项1期临床试验旨在研究SAb-142的安全性、耐受性、药动学和免疫原性,SAb-142是一种人源抗胸腺细胞免疫球蛋白,用于延缓1型糖尿病(T1D)的发病或进展。
MIAMI BEACH, Fla., April ...
暂无评论